GlassScriptPhysician profile
Dolores M Shoback
NPI 1508821208
$62,682.00
in general payments reported to CMS, 2019-2025
7 companies · $18K in 2025
The $18K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $88.00 · 2021: $4,930 · 2022: $3,395 · 2023: $35K · 2024: $1,523 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Consulting Fee: $4,080 · Travel and Lodging: $2,132 · Food and Beverage: $962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $47,094.69 |
| Consulting Fee | $4,080.00 |
| Travel and Lodging | $2,132.29 |
| Food and Beverage | $962.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $53,561.52 | 2022-2025 | Yorvipath, Skytrofa |
| Takeda Pharmaceuticals U.S.A., INC. | $5,290.00 | 2021-2025 | Natpara (Parathyroid Hormone) |
| Novo Nordisk INC | $1,870.00 | 2021 | |
| Chugai Pharmaceutical Co., LTD. | $1,022.48 | 2025 | |
| Novo Nordisk Health Care Ag | $850.00 | 2021 | |
| Amgen INC. | $88.00 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dolores Shoback listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.